Advertisement

New Blood Marker of Endoscopic Disease Activity—A Step Forward in Treating Crohn’s Disease to Target?

  • Manasi Agrawal
    Affiliations
    The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Ryan C. Ungaro
    Affiliations
    The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
  • Jean-Frederic Colombel
    Correspondence
    Correspondence Address correspondence to: Jean-Frederic Colombel, The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York NY 10029.
    Affiliations
    The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York
    Search for articles by this author
Published:December 19, 2019DOI:https://doi.org/10.1053/j.gastro.2019.12.015
      See “Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins,” by D'Haens G, Kelly O, Battat R, et al, on page 515.
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • D'Haens G.
        • Kelly O.
        • Battat R.
        • et al.
        Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins.
        Gastroenterology. 2020; 158: 515-526
        • Peyrin-Biroulet L.
        • Sandborn W.
        • Sands B.E.
        • et al.
        Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target.
        Am J Gastroenterol. 2015; 110: 1324-1338
        • Colombel J.-F.
        • Panaccione R.
        • Bossuyt P.
        • et al.
        Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
        Lancet. 2017; 390: 2779-2789
        • Ungaro R.C.
        • Yzet C.
        • Bossuyt P.
        • et al.
        Sa1812 – endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM.
        Gastroenterology. 2019; 156: S-411
        • Rex D.K.
        • Boland C.R.
        • Dominitz J.A.
        • et al.
        Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer.
        Gastroenterology. 2017; 153: 307-323
        • Mosli M.H.
        • Zou G.
        • Garg S.K.
        • et al.
        C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.
        Am J Gastroenterol. 2015; 110 (quiz 20): 802-819
        • Kalla R.
        • Kennedy N.A.
        • Ventham N.T.
        • et al.
        Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases.
        Am J Gastroenterol. 2016; 111: 1796-1805
        • Meuwis M.A.
        • Vernier-Massouille G.
        • Grimaud J.C.
        • et al.
        Serum calprotectin as a biomarker for Crohn's disease.
        J Crohns Colitis. 2013; 7: e678-e683
        • Faubion Jr., W.A.
        • Fletcher J.G.
        • O'Byrne S.
        • et al.
        EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
        Am J Gastroenterol. 2013; 108: 1891-1900
        • Yablecovitch D.
        • Kopylov U.
        • Lahat A.
        • et al.
        Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis.
        Ther Adv Gastroenterol. 2019; 12 (1756284819881590)
        • Heida A.
        • Knol M.
        • Kobold A.M.
        Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity.
        Clin Gastroenterol Hepatol. 2017; 15: 1742-1749.e2

      Linked Article